WO2009102611A3 - Methods of predicting responsiveness of ms patients to immune-based therapy - Google Patents

Methods of predicting responsiveness of ms patients to immune-based therapy Download PDF

Info

Publication number
WO2009102611A3
WO2009102611A3 PCT/US2009/033180 US2009033180W WO2009102611A3 WO 2009102611 A3 WO2009102611 A3 WO 2009102611A3 US 2009033180 W US2009033180 W US 2009033180W WO 2009102611 A3 WO2009102611 A3 WO 2009102611A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune
based therapy
patients
methods
concentration
Prior art date
Application number
PCT/US2009/033180
Other languages
French (fr)
Other versions
WO2009102611A2 (en
Inventor
Hideki Garren
William Robinson
Original Assignee
Bayhill Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayhill Therapeutics, Inc. filed Critical Bayhill Therapeutics, Inc.
Publication of WO2009102611A2 publication Critical patent/WO2009102611A2/en
Publication of WO2009102611A3 publication Critical patent/WO2009102611A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides methods for predicting the responsiveness of a patient exhibiting symptoms of multiple sclerosis (MS) to an immune-based therapy by measuring the concentration of total IgG in cerebrospinal fluid (CSF) and comparing to a predetermined threshold concentration level. Patients presenting with a baseline concentration of total IgG in CSF above the predetermined threshold level are predicted to respond favorably to immune-based therapies useful for treating MS.
PCT/US2009/033180 2008-02-15 2009-02-05 Methods of predicting responsiveness of ms patients to immune-based therapy WO2009102611A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2913808P 2008-02-15 2008-02-15
US61/029,138 2008-02-15

Publications (2)

Publication Number Publication Date
WO2009102611A2 WO2009102611A2 (en) 2009-08-20
WO2009102611A3 true WO2009102611A3 (en) 2009-12-30

Family

ID=40957451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/033180 WO2009102611A2 (en) 2008-02-15 2009-02-05 Methods of predicting responsiveness of ms patients to immune-based therapy

Country Status (1)

Country Link
WO (1) WO2009102611A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308459A (en) * 1991-03-07 1994-05-03 Baxter Diagnostics Inc. Biosynthetic cerebrospinal fluid control and method of use
US20060051345A1 (en) * 2004-06-04 2006-03-09 Genentech, Inc. Method for treating multiple sclerosis
US20060247175A1 (en) * 1991-10-22 2006-11-02 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
WO2007147011A2 (en) * 2006-06-13 2007-12-21 Bayhill Therapeutics, Inc. Polynucleotide therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308459A (en) * 1991-03-07 1994-05-03 Baxter Diagnostics Inc. Biosynthetic cerebrospinal fluid control and method of use
US20060247175A1 (en) * 1991-10-22 2006-11-02 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US20060051345A1 (en) * 2004-06-04 2006-03-09 Genentech, Inc. Method for treating multiple sclerosis
WO2007147011A2 (en) * 2006-06-13 2007-12-21 Bayhill Therapeutics, Inc. Polynucleotide therapy

Also Published As

Publication number Publication date
WO2009102611A2 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
BR112012008665A2 (en) cancer treatment
MX2014001246A (en) Identification of gene expression profile as a predictive biomarker for lkb1 status.
AR084831A1 (en) ANTICANCER THERAPY THROUGH QUINASA INHIBITORS
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
BR112015022472A2 (en) method and system for predicting response to treatments for mental disorders
BR112015017403A2 (en) anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
WO2013096407A3 (en) Monitoring activation times for use in determining pacing effectiveness
MX343324B (en) Assays for detecting neutralizing autoantibodies to biologic therapy with tnf alpha.
BR112014019349A8 (en) OUTCOME PREDICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
MX339427B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer.
MX356797B (en) USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN.
BR112015012482A2 (en) Assays for detecting neutralizing autoantibodies to biological therapy
BR112015022473A2 (en) method and system for predicting response to pain treatments
WO2012129457A3 (en) Diagnostic and treatment methods using a ligand library
WO2014052921A3 (en) Patient health record similarity measure
WO2013158821A3 (en) Methods of treating ankylosing spondylitis using il-17 antagonists
WO2014040891A3 (en) Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation
WO2010116003A3 (en) Method for predicting the response of non-small cell lung cancer patients to targeted pharmacotherapy
WO2014145254A3 (en) Falz for use as a target for therapies to treat cancer
WO2009102611A3 (en) Methods of predicting responsiveness of ms patients to immune-based therapy
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy
IN2014MN01795A (en)
WO2013166030A3 (en) Detecting complement activation
MX2014002144A (en) A method for predicting clinical benefit in the treatment of neurodevelopmental, neurological or neuropsychiatric disorders.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09710806

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09710806

Country of ref document: EP

Kind code of ref document: A2